Antihypertensive medication and their impact on cancer incidence: a mixed treatment comparison meta-analysis of randomized controlled trials

@article{Coleman2008AntihypertensiveMA,
  title={Antihypertensive medication and their impact on cancer incidence: a mixed treatment comparison meta-analysis of randomized controlled trials},
  author={Craig I. Coleman and William L. Baker and Jeffrey Kluger and C. Michael White},
  journal={Journal of Hypertension},
  year={2008},
  volume={26},
  pages={622–629}
}
Objective The aim of this article is to determine the association between commonly used antihypertensive agents and the incidence of cancer. Methods We conducted a mixed treatment comparison meta-analysis of randomized, controlled (placebo, active, or untreated control) trials of antihypertensive drugs. A systematic literature search was conducted through June 2007. The primary outcome measure assessed was the incidence of cancer. Mixed treatment comparison meta-analysis was used to combine… 
View on Wolters Kluwer
ncbi.nlm.nih.gov
62 Citations
Highly Influential Citations
2
Background Citations
9
Results Citations
3

62 Citations

Citation Type

Citation Type

Original article Further data on beta-blockers and cancer risk: observational study and meta-analysis of randomized clinical trials
TLDR
Exposure to -blocker treatment and the incidence of cancer, using two different approaches (epidemiological study and metaanalysis of clinical trials), shows that exposure to - blockers was associated with a reduced overall risk of cancer.
Which, if any, antihypertensive agents cause cancer?
TLDR
There is no convincing evidence that any of the individual antihypertensives in clinical use, at the dosages and duration tested, lead to higher rates of cancer, but the medical literature has long hypothesized potentially carcinogenic effects ofAntihypertensive agents.
Potential increased risk of cancer from commonly used medications: an umbrella review of meta-analyses.
TLDR
No medication or class had substantial and consistent evidence for increased risk of malignancy and such risks are unlikely to be possible to document robustly unless very large, collaborative studies with standardized analyses and no selective reporting are carried out.
Antihypertensive medications and survival in patients with cancer: a population-based retrospective cohort study.
The Risk for Lung Cancer Incidence with Calcium Channel Blockers: A Systematic Review and Meta-Analysis of Observational Studies
TLDR
Exposure to CCB use is associated with an increased risk of lung cancer, and the paucity of data on the long-term effects of chronic exposure to CCBs is reason for concern and warrant further investigation.
Effect of Biologic Agents on Non-PASI Outcomes in Moderate-to-Severe Plaque Psoriasis: Systematic Review and Meta-Analyses
TLDR
Individual biologics and classes showed consistent benefits across non-PASI health outcomes in patients with moderate-to-severe plaque psoriasis while MTC meta-analyses suggested that some differences exist.
The incidence of cancer deaths among hypertensive patients in a large Chinese population: a cohort study.
Angiotensin receptor blocker therapy and risk of cancer.
  • K. Teo
  • Medicine
    Journal of hypertension
  • 2013
TLDR
There was no evidence to indicate an increased risk of lung cancer among new users of ARBs compared to nonusers, and the authors had a sound strategy in using a large sample size of over a million patients and in using appropriate statistical methods to compare the users versus nonusers as controls.
The use of drugs acting on the renin–angiotensin system and the incidence of pancreatic cancer
TLDR
The use of ARBs and ACEIs was not associated with an overall decreased risk of pancreatic cancer when compared with patients using other antihypertensive drugs, and additional research is needed to determine whether ARBs may confer a short-term protective effect.
The effect of renin-angiotensin-system inhibition on survival and recurrence of N3+ breast cancer patients.
TLDR
This is the second study showing that the use of ACE inhibitors/ARBs may be effective in N3 BC, and to the best of the authors' knowledge this is the first to show that RAS inhibition was associated with reduced risk of pathologic N3BC recurrence.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 87 REFERENCES
Statins and cancer risk: a meta-analysis.
CONTEXT Statins are cholesterol-lowering drugs that have been proven in randomized controlled trials to prevent cardiac events. Recent retrospective analyses have suggested that statins also prevent…
Antihypertensive Therapy and Cancer Risk
TLDR
It is suggested that the management of hypertension should continue according to current treatment guidelines with little fear of any substantial cancer risk, as the available evidence seems to favour a neutral effect on cancer development and death rate.
Hypertension, antihypertensive therapy and renal-cell cancer: a meta-analysis.
TLDR
Although the pooled estimates show that both, hypertension and hypertensive therapy, are statistically associated with increased risk of RCC, experimental data and a closer look on the original data from epidemiologic literature, show that available evidence are still uncertain and need to be further investigated.
Antihypertensive therapy and the risk of malignancies.
TLDR
With the exception of diuretics and renal cell carcinoma, the association between antihypertensive drugs and malignancy was either low grade (rauwolfia), uncertain (atenolol), absent (ACE inhibitors), or absent with a yet to be investigated inverse association (calcium antagonists).
A Systematic Review and Meta‐analysis of the Incidence of Cancer in Randomized, Controlled Trials of Verapamil
TLDR
There is no statistically significant increased risk of cancer or deaths with verapamil compared with active controls or placebo, and sensitivity analysis for the 9 trials 24 weeks' duration or longer gave similar results.
Antihypertensive Drug Use and The Risk of Prostate Cancer (Canada)
TLDR
The results suggest that BBs and long-term use of ABs may prevent PC whereas calcium channel blockers or angiotensin-converting enzyme inhibitors do not influence PC risk.
Is there an association between hypertension and cancer mortality?
A Cohort Study of Antihypertensive Medication Use and Breast Cancer Among Danish Women
TLDR
There was no statistically significant association between ever use of any AHT overall or any specific class of AHT (diuretics, beta blockers, calcium channel blockers), angiotensin converting enzyme (ACE) inhibitors, and angiotENSin II antagonists and breast cancer.
Cancer risk of hypertensive patients taking calcium antagonists
TLDR
A retrospective analysis of cancer in patients of the Glasgow Blood Pressure Clinic prescribed either a calcium antagonist or other antihypertensive drugs (non-calcium antagonist group) lends no support to the suggestion that calcium antagonists cause cancer.
Hypertension, diuretics and breast cancer risk
TLDR
A positive association between treated hypertension, diuretic use and breast cancer risk among women aged 50–75 years is found and is supported by a case–control study.
...
1
2
3
4
5
...